

Amendments to the Claims:

1-28. (Cancelled)

29. (Currently amended) A combination for treating a vascular proliferative disease in a patient comprising a balloon catheter and a nucleic acid comprising a gene encoding a single cyclin-dependent kinase inhibitor, wherein the cyclin-dependent kinase inhibitor is p27.

30. (Currently amended) The combination of claim 29, wherein the balloon catheter is a single balloon catheter.

31. (Currently amended) The combination of claim 29, wherein the balloon catheter is a double balloon catheter.

32. (Previously amended) The combination of claim 29, wherein the nucleic acid is an expression vector.

33. (Previously amended) The combination of claim 29, wherein a viral particle contains the nucleic acid.

34. (Previously amended) The combination of claim 29, further comprising a liposome.

35. (Cancelled)

36. (Previously amended) The combination of claim 29, wherein the nucleic acid further comprises a gene encoding a cytotoxic agent.

37. (Previously amended) The combination of claim 36, wherein the cytotoxic agent is selected from the group consisting of thymidine kinase, cytosine kinase, cytosine deaminase, and nitric oxide synthetase.

38. (Previously amended) The combination of claim 37, wherein cytotoxic agent is thymidine kinase.

39. (Previously amended) The combination of claim 36, wherein the gene encoding p27 and the gene encoding the cytotoxic agent are operatively linked.

40. (Previously amended) The combination of claim 39, wherein the gene encoding p27 and the gene encoding the cytotoxic agent are operatively linked such that they form a fusion protein.

41. (Previously amended) The combination of claim 40, wherein the fusion protein is a p27-thymidine kinase fusion protein.

42. (Previously amended) The combination of claim 36, wherein the gene encoding p27 and the gene encoding the cytotoxic agent form a dicistronic construct.